On World Cancer Day, we recognize the importance of cancer research in expanding early access to investigational therapies and generating evidence that informs progress in oncology care. At Lambda Therapeutic Research and Novum Pharmaceutical Research Services, we work closely with global biotech and pharmaceutical companies to support oncology clinical trials that address unmet medical needs and aim to improve outcomes for patients.
Cancer and World Cancer Day
Cancer continues to be a major global health challenge. According to international estimates, cancer remains one of the leading causes of death worldwide, with an ongoing rise in new cases and related mortality. In 2022, about 20 million new cancer cases were diagnosed globally, and nearly 9.7 million people died from the disease. Projections indicate that the number of new cancer cases could reach over 35 million by 2050 due to population growth and changing risk factor exposures. Around 70% of cancer deaths occur in low- and middle-income countries, highlighting the uneven global burden of disease.
Observed each year on February 4, World Cancer Day unites individuals, organizations, and healthcare systems worldwide to raise awareness, strengthen education, and encourage action across the cancer care continuum. The World Cancer Day theme for 2025 to 2027, “United by Unique,” places people at the center of cancer care and recognizes that every cancer journey is shaped by individual biology, circumstances, and lived experience. This focus aligns closely with our approach at Lambda and Novum. We aim to design and conduct clinical trials that reflect patient diversity and address individual needs while maintaining scientific and regulatory rigor. Through collaboration with investigators, sponsors, and patient communities, we support the development of oncology therapies that can improve outcomes and quality of life. On World Cancer Day, we reaffirm our support for global efforts to advance cancer research, expand access to care, and improve patient outcomes through responsible and patient focused clinical development.
Cancer research: Hope for the Future
Clinical trials are central to progress in cancer research and to improving understanding of the disease across its many forms. Study design, protocol feasibility, patient engagement, and safety oversight are critical components that directly influence trial quality and participant experience. A patient focused approach helps support enrollment, retention, and meaningful outcomes while maintaining scientific and regulatory standards.
At Lambda and Novum, we apply our clinical research expertise to support oncology development programs across phases. Our teams work closely with sponsors and investigators to manage operational complexity and support studies that address unmet medical needs.
On World Cancer Day, and throughout the year, we continue to support efforts that advance cancer research, strengthen clinical evidence, and contribute to improved access to effective therapies for patients worldwide.
Advancing Oncology Clinical Trials
We understand that participating in a clinical trial can be a complex and sometimes daunting experience for cancer patients. That’s why we prioritize a patient-centric approach in everything we do.
Strategic Site Selection
Selecting the right clinical trial sites is crucial for the success of cancer clinical trials. We prioritize this process, focusing on experienced investigators and site staff well-versed in clinical oncology, especially in treating cancer. These carefully chosen sites ensure optimal data collection and a smoother trial experience for recruited patients.
Streamlining Recruitment & Retention
Enhancing trial success, we employ patient-centric initiatives and care coordinators, addressing barriers for a supportive participant experience. Recruitment and retention challenges are effectively tackled through these coordinators’ close work with participants, leading to improved patient outcomes and better data collection.
Innovative Trial Protocols
Innovation is at the heart of our trial protocols, ensuring a patient-centric experience. We design innovative and patient-friendly protocols that enhance the trial journey. By incorporating the latest advancements and considering the unique needs of cancer patients, we strive for improved outcomes and seamless data collection.
Overcoming the Complexities of Oncology Clinical Trials
At Lambda & Novum, our commitment to advancing cancer treatment is reflected in our extensive experience in oncology clinical trials. With a strong portfolio that includes over 290+ clinical trials spanning 15+ therapeutic areas, oncology remains a cornerstone of our expertise.
80+
Oncology Trials
7000+
Patients
1000+
Global Sites
Lambda has a proven track record in cancer clinical trials, having conducted 80+ trials across a range of indications. Our expertise spans common cancers such as breast cancer (including metastatic and triple-negative), lung cancer (NSCLC), and prostate cancer, as well as complex and less common cancers, including ovarian, gastric, and bladder cancers. Additionally, we have experience in hematological malignancies (such as lymphoma and myelodysplastic syndrome), pediatric cancers, and various other conditions related to cancer or its treatment.
With experience enrolling over 7000 patients across a network of 1000+ sites, we efficiently manage large-scale, complex trials while upholding the highest standards of patient care and data integrity. Our expertise also extends to biosimilar development, where we have significant experience with key oncology therapies, including Bevacizumab, Denosumab, Trastuzumab, Pertuzumab, Rituximab, Daratumumab and Trastuzumab Emtansine.
Our end-to-end capabilities, including medical imaging, biostatistics, bioanalytical & pharmacovigilance services, allow us to provide comprehensive solutions for our clients. By maintaining the highest standards of quality and regulatory compliance, we ensure reliable, high-quality trial outcomes. Our successful regulatory submissions to the USFDA, EMA, and ANVISA highlight our deep understanding of global regulatory frameworks and our expertise in navigating the complexities of the approval process.
Transform Your Oncology Trials with Our Proven Expertise
At Lambda and Novum, we navigate the complex clinical trial landscape, leveraging our extensive expertise, bringing hope, and accelerating breakthroughs for patients. Leverage Lambda & Novum’s extensive experience & proven track record to accelerate your Oncology clinical trials. Let’s make Progress together in the Fight Against Cancer. Get in touch with our team of experts.
About Lambda
Lambda & Novum delivers comprehensive, end-to-end clinical research services to the innovator, biotech, and generic pharmaceutical industries worldwide. With a strong global presence in India, the USA, Canada, the UK, Spain and Poland, we bring specialized expertise to every project. Our focus on secure IT infrastructure and automation ensures timely project delivery and strict adherence to international regulatory standards. Lambda’s exemplary regulatory track record includes over 60 successful inspections and audits by esteemed authorities, including the USFDA, EMEA, MHRA, EU member states, and other global regulatory bodies, in the past five years.
References:
- https://www.who.int/news-room/fact-sheets/detail/cancer
- https://www.worldcancerday.org/what-cancer
- https://www.cancer.org/content/dam/cancer-org/research/cancer-facts-and-statistics/global-cancer-facts-and-figures/global-cancer-facts-and-figures-2024.pdf
- https://www.who.int/news/item/01-02-2024-global-cancer-burden-growing–amidst-mounting-need-for-services
